Correlation between blood lipid levels and bone mineral density in men with hypertension in Xinjiang

doi:10.3969/j.issn.2095-4344.2015.20.007

Abstract

Abstract:

BACKGROUND: Studies have shown that there is a certain correlation between blood lipid levels and bone mineral density in postmenopausal women, but their correlation in men is an open question, which has been less reported.
OBJECTIVE: To investigate the relationship between blood lipid levels and bone mineral density in Han and Uygur men with hypertension in Urumqi of Xinjiang Uygur Autonomous Region, as well as correlation of blood lipid levels with osteoporosis and osteopenia and difference between ethnics.
METHODS: A total of 193 male patients with hypertension were categorized into Uygur (n=73) and Han (n=120) groups. Each group was subdivided into osteoporosis or osteopenia group and non-osteoporosis group. Bone mineral density and blood lipid level were analyzed and compared between groups. The correlation between osteoporosis and risk factors was analyzed using logistic regression method.
RESULTS AND CONCLUSION: In Uygur hypertension men with osteoporosis or osteopenia, total cholesterol level was positively correlated with the bone mineral density of the femoral neck (r=0.43, P=0.01) and Ward’s area (r=0.42, P=0.01); while there were no relationships between blood lipid levels and bone mineral density in Han hypertension men. When a Logistic regression analysis was performed, only total cholesterol level was found to be associated with the presence of osteoporosis or osteopenia after adjustment for body mass index, age and ethnics (OR=1.48, P=0.03). The blood lipid level is associated with bone mineral density in Han and Uygur men with hypertension from Urumqi of Xinjiang Uygur Autonomous Region, which can affect the presence of osteoporosis.

Key words: Hypertension, Bone Density, Osteoporosis, Cholesterol

CLC Number:

R318

Li Huan, Da Na, Liang Jie. Correlation between blood lipid levels and bone mineral density in men with hypertension in Xinjiang [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(20): 3152-3157.

Figures/Tables 3

References

[1] Kiel DP, Kauppila Ll, CuppIes LA, et al. Bone loss and the progression of abdominal artic calcification over a 25-year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68:271-276.

[2] Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273-278.

[3] Fleet JC, Hock JM. Identification of osteocalcin mRNA in nonosteoid tissue of rats and humans by reverse transcription-polymerase chain reaction. J Bone Miner Res. 1994;9:1565-1573.

[4] Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003;73:15-20.

[5] Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol. 2001;12: 555-560.

[6] Giachelli CM, Ljaw L, Murry CE, et al. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci. 1995;760:109-126.

[7] Fleet JC, Hock JM. Identification of osteocalcin mRNA in nonosteoid tissue of rats and humans by reverse transcription-polymerase chain reaction. J Bone Miner Res. 1994;9:1565-1573.

[8] Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol. 2001;88:20E-22E.

[9] 姚银辉,陈慧慧,鲁澄宇.他汀类药物对糖尿病性骨质疏松患者骨钙素和骨密度影响的系统评价[J].中国骨质疏松杂志,2012, 18(3): 263-268.

[10] 郑强.雌激素与绝经后的骨质疏松[J].国外医学:老年医学分册, 1998,19(3):132.

[11] 唐瑛.白细胞介素-6与绝经后骨质疏松的研究进展[J].中国中医骨伤科杂志,1998,6(14):57.

[12] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,5(3):42-93.

[13] Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure and bone-mineral loss in elderly white women:a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354:971-975.

[14] 史大治,王曦云,宋成伟.中老年男性高血压病与骨质疏松的关系[J].中国实用医药,2012,7(18): 55-56.

[15] 张在勇,李自成.高血压与骨质疏松发病机制中细胞因子的变化[J].医学综述,2011,17(3): 327-330.

[16] Bartels T, Beitz J, Hein W, et al. Changes in the spongiosa density in the femoral head of rabbits in atherosclerosis. Beitr Orthop Traumatol. 1990;37:291-297.

[17] Broulik PD, Kapitola J. Interrelations between body weight,cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr Regul. 1993;27:57-60.

[18] 18 Tarakida A,Iino K, Abe K, et al. Hypercholesterolemia accelerates bone loss in postmenopausal women. Climacteric. 2011;14(1):105-111.

[19] 程幼夫,李婷欣.体检人群骨密度检测与血脂异常的相关性分析[J].中华健康管理学杂志,2012,6(4):268-269.

[20] Adami S, Braga V, Zamboni M, et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int. 2004;74(2):136-142.

[21] 张峰.2型糖尿病患者血脂水平与骨密度的相关性[J].蚌埠医学院学报,2013,38(2):170-172.

[22] 高飞,杨静,师天燕,等.绝经女性血脂与腰椎骨密度关系的研究[J].中南医学科学杂志,2012,40(5):480-483.

[23] D’Amelio P, Pescarmona GP, Gariboldi A, et al. High density lipoproteins (HDL) in women with postmenopausal osteoporosis:a preliminary study. Menopause. 2001;8: 429-432.

[24] 崔双,薛昊罡.绝经后女性骨质疏松患者骨密度与血脂和护骨素的相关性[J].中国老年学杂志,2012,32:2051-2053.

[25] Yamaguchi T, Sugimoto T, Yano S, et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J. 2002; 49:211-217.

[26] 郑延松,王凡,赛晓勇,等.成人健康体检者骨密度相关因素分析[J].中华健康管理学杂志, 2010,4:340-343.

[27] 何书励,楼慧萍,杜颖,等.体检人员的生化数据与骨密度指标分析[J].中华健康管理学杂志,2012,6(1):28-31.

[28] 曾柱文,何晓辉.老年男性血脂水平、心血管疾病与骨密度的关系[J].中国社区医师•医学专业,2012,33(14):131-132.

[29] 张秀珍,王博,杨军,等.2型糖尿病患者伴骨质疏松与血脂的关系[J].中华骨质疏松和骨矿盐疾病杂志,2008,1(2):107-112.

[30] 王雪,叶志明,田剑,等.原发性高血压患者骨量减少机制初探[J].首都医科大学学报,2001, 22(10):46-47.

[31] Martineau C, Martin-Falstrault L, Brissette L, et al. Gender- and region-specific alterations in bone metabolism in Scarb1-null female mice. J Endocrinol. 2014;222(2):277-288.

[32] Zheng YJ, Chen S, Li ZQ, et al. The relationship of vitamin D endocrine system and estrogen receptor expression with bone mineral density in initial systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi. 2010;49(4):309-312.

[33] Cederroth CR, Nef S. Fetal programming of adult glucose homeostasis in mice. PLoS One. 2009;4(9):e7281.

[34] Buday B, Kulcsár E, Literáti Nagy B, et al. The role of osteocalcin in the connection of bone and glucose metabolism in humans. Orv Hetil. 2008;149(52):2453-2461.

[35] Movérare-Skrtic S, Venken K, Andersson N, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity (Silver Spring). 2006;14(4):662-672.

[36] Maeda T, Ke HZ, Simmons H, et al. Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin Calcium. 2004;14(10):85-93.

[37] Sapir-Koren R, Livshits G, Kobyliansky E. Genetic effects of estrogen receptor alpha and collagen IA1 genes on the relationships of parathyroid hormone and 25 hydroxyvitamin D with bone mineral density in Caucasian women. Metabolism. 2003;52(9):1129-1135.

[38] Saito T, Yoshizawa M, Yamauchi Y, et al. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung. 2003;53(7):507-514.

[39] Dowsett M, Ellis MJ. Role of biologic markers in patient selection and application to disease prevention. Am J Clin Oncol. 2003; 26(4):S34-S39.

[40] Takayanagi R, Goto K, Suzuki S, et al. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mech Ageing Dev. 2002;123(8):1107-1114.